NCT07843342|Recruiting
Human Absorption Study of Liposomal Glucosamine Supplements
Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements
Loading search results
Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements
Sponsor study identifier
interventional
16
1 country
1
Study Start
October 21, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 29, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The objective of this study is to evaluate the effects of liposomal encapsulation using different ratios of gum arabic and lecithin on the bioavailability of a liquid glucosamine supplement in humans.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 29, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 21, 2026
Actual (reported)September 28, 2026
Actual (reported)October 21, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 29, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Plasma glucosamine level (ng/mL)
Plasma glucosamine levels will be measured at fasting and at 0.5, 1, 2, 4, 8, and 24 hours post-intake.
at 24 hours after taking test sample
One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine.
One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine.
One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine.
The formulation primarily consists of glucosamine HCl, a high proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
High-Emulsified Liposomal Glucosamine Liquid
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
View registry recordFormulated product
Low-Emulsified Liposomal Glucosamine Liquid
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
View registry recordTCI Co., Ltd
Taipei, 114, Taiwan
Tong-Lin Wu
TCI Co., Ltd.
First Submitted
September 21, 2026
First Posted
September 28, 2026
Study Start
October 21, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2026
Three tablets will be administered per dose, with each tablet containing 500 mg of glucosamine.
The formulation primarily consists of glucosamine HCl, a low proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology.
The formulation primarily consists of glucosamine HCl and is not processed using the patented Double Nutri Liposomal technology.
The tablet formulation primarily consists of glucosamine HCl and is not processed using liposomal technology.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 29, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 28, 2026
Record last verified: 2026-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: